Summary of ProMetic Life Sciences Inc.'s Presentation at Biotech Showcase 2010

MONTREAL, QUEBEC, CANADA--(Marketwire - January 12, 2010) - - Baseline revenues (excluding P-Capt® and PBI-1402) estimated at $22M

- Latest announcement from FDA on ESAs further strengthens positioning of PBI-1402

- Increasing interest in ProMetic's unique prion reduction technology

ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today provided a summary of ProMetic's presentation at the Biotech Showcase 2010 conference. All amounts are in Canadian dollars.

Projected outlook for 2010

Excluding potential revenues from P-Capt® sales, the partnering of PBI-1402, and revenues from other business development initiatives, ProMetic's revenue guidance for its business activities in 2010 is $22 M.

With the United Kingdom's Advisory Committee on the Safety of Blood, Tissues and Organs' ("SaBTO") recommendation to use the P-Capt® prion reduction filter to protect children from variant Creutzfeldt-Jakob disease ("vCJD") blood transmission, the Company fully expects revenue from P-Capt® to have an additional impact in 2010.

Business development deals are also expected to materialize in 2010 and contribute further growth.

Management is nevertheless continuing to apply its cost-reduction measures to ensure that its core business activities alone, bring the Company closer to profitability, without any revenues from PBI-1402 and P-Capt®.

PBI-1402, a novel, first-in-class drug

The Food and Drug Administration ("FDA") announced last week that it would review the safety of the widely used anemia drugs (ESAs) after another clinical trial suggested that high doses of one of the drugs might cause strokes.

Recent validation with the FDA that PBI-1402 is a novel, first-in-class drug that differs from existing approved medications (ESAs) for the treatment of anemia, clarifies the regulatory pathway and supports partnering activities.

Given that PBI-1402 reduces tumor growth and does not elevate hemoglobin to potentially dangerous levels, it provides unique positioning strategies that the Company is actively pursuing.

Prion Capture Products - commercial expansion

In late November 2009, SaBTO had recommended the adoption of the P-Capt® prion reduction filter to pre-treat red blood cells destined for children born since 1 January 1996, for prevention of transmission of vCJD.

This was the second recommendation from SaBTO in 2009 favouring ProMetic. In July, SaBTO had also recommended the use of prion depleted plasma for transfusion and such specifications can only be met by OctaplasLG®, a product manufactured by Octapharma and also relying on ProMetic's prion capture technology.

MacoPharma SA, ProMetic's partner in the commercialization of the P-Capt® filter is interacting with individuals at various government levels in the preparation for the formal implementation of the P-Capt® for this group.

Last week, ProMetic announced its latest collaboration agreement with Abraxis BioScience, Inc. for the development and commercialization of new applications deriving from ProMetic's prion capture technology platform. This collaboration will allow ProMetic to increase its commercial reach and expand the use of prion capture products beyond Europe. Abraxis will also contribute to ProMetic additional financial and organizational resources in product development, regulatory approval process, clinical trials, etc.

.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 25 of ProMetic's Annual Information Form for the year ended December 31, 2008, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.